The Canavan disease program received RMAT Designation based on preliminary clinical evidence from the CANaspire Phase 1/2 clinical trial. BridgeBio will leverage the benefits of RMAT designation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback